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Abstract
Objective: To compare the anesthetic action of 0.5% bupivacaine in relation to 4% articaine, both with 1:200,000 
epinephrine, in the surgical removal of lower third molars. As a secondary objective hemodynamic changes using 
both anesthetics were analyzed.
Study Design: Triple-blind crossover randomized clinical trial. Eighteen patients underwent bilateral removal of 
impacted lower third molars using 0.5% bupivacaine or 4% articaine in two different appointments.  Preoperative, 
intraoperative and postoperative variables were recorded. Differences were assessed with McNemar tests and 
repeated measures ANOVA tests. 
Results: Both solutions exhibited similar latency times and intraoperative efficacy. Statistical significant lower 
pain levels were observed with bupivacaine between the fifth (p=0.011) and the ninth (p=0.007) postoperative 
hours. Bupivacaine provided significantly longer lasting soft tissue anesthesia (p<0.05). Systolic blood pressure 
and heart rate values were significantly higher with articaine.
Conclusions: Bupivacaine could be a valid alternative to articaine especially due to its early postoperative pain 
prevention ability.
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Introduction
Profuse scientific literature exists addressing different 
aspects of third molar treatment such as indications for 
extraction (1-3), complications (4), as well as multiple 
studies comparing effectiveness of different treatments 
protocols to control postoperative pain or edema (5,6). 
Third molar extractions have proven to be a suitable 
model to compare treatment approaches in a randomized 
controlled design (7). The ease to find individuals 
needing to undergo two symmetrical surgeries and the 
fact that patients act as their own control make this model 
very popular. This split-mouth design reduces possible 
research bias by avoiding physiological and psychological 
differences between tested individuals (8). 
Local anesthetics (LA) have been broadly compared 
using this model (9-18). A variety of LA have been 
developed to satisfy specific requirements of different 
clinical procedures (19). Articaine is a common LA 
used in oral surgery. It belongs to the amide group of 
LA and has a fast onset and an adequate duration with 
little side effects (20). Even though it is considered a long 
lasting anesthetic there are others, such as bupivacaine, 
etidocaine or ropivacaine, with more extended anesthetic 
effects. Bupivacaine is often chosen in prolonged 
operations due to its extensive anesthetic period (13,17). 
Moreover, some authors have attributed it the ability to 
attain longer postoperative analgesic periods, reducing 
analgesic requirements in the early postoperative hours 
when the maximum pain intensity is reached (10,21,22). 
This feature is of major importance since one of the 
patient’s main concerns when undergoing a surgical 
procedure is the onset of postoperative pain (23). 
Due to the clinical relevance of bupivacaine’s extended 
postoperative analgesic effect further analysis is needed. 
To our knowledge only a couple of clinical trials have 
compared bupivacaine with articaine for lower third 
molar removal. (15,24) Therefore, the aim of this study 
was to compare the intraoperative and postoperative 
anesthetic behavior of 0.5% bupivacaine in relation to 
4% articaine, both with 1:200,000 epinephrine, in the 
surgical removal of symmetrically impacted lower 
third molars. As a secondary objective hemodynamic 
changes observed during the different surgical phases 
using both anesthetics were analyzed.
Material and Methods
All patients provided written informed consent during 
the recruitment period of the study. The protocol of this 
study was approved by the Ethics Committee of the 
Dental School of the University of Barcelona. Calculation 
of sample size was performed using G*power 3.1.0 
software, assuming α error =0.05, power= 95% and 
estimated effect size =0.4. Sixteen patients were needed. 
To compensate for possible losses, study population 
consisted of 20 individuals with symmetrically 
positioned full bony impacted lower third molars, 
recruited from 25 eligible subjects. Eligibility criteria 
included ASA I or II patients, aged between 18 and 40 
years, who presented bilateral impacted lower third 
molars, which required for their removal flap elevation, 
bone removal and tooth sectioning. Exclusion criteria 
included allergy to local anesthetics or any other 
medication, pregnancy or current lactation, heart rate > 
110 bpm. or < 60 bpm., systolic arterial pressure > 150 
mm Hg or < 100 mm Hg, diastolic arterial pressure > 
100 mm Hg or < 60 mm Hg, oxygen saturation < 96%, 
pain, swelling or infectious signs associated to the third 
molar site immediately before surgery, any drug intake 
during the previous 15 days to the surgery, and surgeries 
lasting less than 15 minutes or longer than 45 minutes. 
The study design comprised a triple-blind scheme. All 
anesthetic carpules were equally manufactured and were 
encoded. The patient, the surgeon and the statistician 
who performed the data analysis did not know which 
anesthetic solution had been used. Each patient required 
a similar surgical treatment for the removal of both 
inferior third molars. The extractions were carried out 
at two different appointments, with at least a month of 
wash out period. The starting time of every surgery 
was 9:00 am. All surgeries were performed by the same 
surgeon and monitored by the same person. 
The anesthetic technique chosen was a regional block 
of the inferior alveolar nerve at the mandibular foramen 
level with a direct technique (18), using a UnijectTM 
syringe (Becton&Dickinson, New Jersey, USA) with a 
35 mm long and 27G Monoprotect XL® needle (Inibsa, 
Barcelona, Spain). Approximately 1.3 cc of the solution 
were deposited close to the mandibular foramen to 
anesthetize the inferior alveolar nerve and the remaining 
0.5 cc were infiltrated while extracting the needle in 
order to anesthetize the lingual nerve. Next, 0.9 cc of 
the anesthetic solution was infiltrated in the buccal 
mucosa around the first and second lower molars to 
guarantee anesthesia and hemostasis of the site. Ten 
minutes after the anesthesia was delivered, thermal 
sensibility of the homolateral lower second molar was 
evaluated positioning a cotton pellet impregnated in 
tetrafluoroethane on the buccal aspect of the tooth. If the 
patient felt thermal stimulation, the anesthetic regional 
block was repeated and second molar pulpal sensibility 
was reevaluated 10 minutes after. Additional amounts 
of anesthetic were administered during the surgery if 
the patient complained about feeling pain. The surgical 
field and all surgical materials were sterile. The surgical 
technique was similar to that described by Leonard (25). 
Patients remained at the clinic for the first postoperative 
hour and were discharged if no complications arose. 
Every patient received a leaflet where the postoperative 
instructions were described. Patients were prescribed 
750 mg of amoxicillin (Amoxicilina Normon EFG 750 
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mg, Normon, Madrid, Spain) and 600 mg of ibuprofen 
(Ibuprofen Normon EFG 600 mg, Normon, Madrid, Spain) 
that had to be taken at 9:00 hours (just before surgery), 
15:00 hours and 23:00 hours for 4 days. Patients were 
instructed to rinse with 0.12% chlorhexidine digluconate 
(Clorhexidina Lacer 0.12%, Lacer, Barcelona, Spain) 3 
times a day for 15 days, starting the day after surgery. 
Metamizol was prescribed as a rescue medication 
(Metamizol Magnésico Normon EFG 575 mg, Normon, 
Madrid, Spain). Patients had to record the date and time 
at which the rescue medication was taken. 
The following data were collected:
1. Onset of anesthetic action (in minutes) determined by: 
1) the loss of pulpal sensibility assessed by a negative 
response to thermal stimuli after positioning a cotton 
pellet impregnated with tetrafluoroethane on the buccal 
aspect of the homolateral lower second molar and 2) 
loss of homolateral retromolar trigone mucosa, lip and 
tongue sensibility to pricking.
2. Total volume of anesthetic solution used during surgery 
and need of additional anesthetic infiltrations (time, 
volume, and anesthetic technique used for reanesthesia).
3. Duration of surgery after anesthetic administration 
(in minutes), which corresponds to the period between 
the first incision until placement of the last suture.
4. Adverse reactions during surgery or during the first 
postoperative week.
5. Intraoperative global pain judged by the patient 
and by the surgeon at the end of surgery in a 5-point 
scale (no pain, light pain, moderate pain, strong pain or 
unbearable pain). 
6. Duration of postoperative anesthesia, represented by 
the lack of sensibility of the lower lip and the tongue. 
Patients recorded the moment at which they noticed 
the initial recovery of lip and tongue sensibility and 
the time at which lip and tongue sensibility had totally 
returned to normality.
7. Subjective pain evaluation, with the aid of a 100-
mm-length visual analogue scale (VAS), with a 0 
anchored by “no pain” and a 100 anchored by “worst 
pain imaginable”. Subjects recorded the intensity of 
postoperative pain at 2 hour intervals starting the 
surgery day at 10 am until 10 pm (10 am, 12 am, 2 pm, 4 
pm, 6 pm, 8 pm, 10 pm), and during de second, third and 
fourth postoperative days only at 10 am and 10 pm. 
8. Amount of rescue analgesic medication (magnesic 
metamizol) needed during the first 4 postoperative days.
9. Systolic and diastolic arterial pressure, heart rate 
and oxygen saturation before surgery, one minute after 
anesthetic infiltration, at tissue incision, at start of 
bone removal, and after suturing. All measurements 
were collected using the same monitoring instrument 
(Guardian BPM-730 M, Megos-Sonmedica, Barcelona, 
Spain) in a noninvasive manner.
Paired t-tests were used to compare duration of surgeries 
and time to onset. Continuous variables were analyzed 
using repeated measures ANOVA. Differences between 
anesthetics for categorical variables were assessed 
with the McNemar test. Statistical significance was 
established at p<0.05. The results were presented as the 
mean ± standard deviation (SD).
Results
Twenty patients were included in the study. Two of the 
participants were withdrawn from the study because 
they did not attend the second surgical appointment, so 
the final sample included eighteen patients (7 men and 
11 women), with a mean age of 23.8 years (SD 5.0 years; 
range 18 to 35 years). No adverse reaction related to the 
anesthetic agent was detected during surgery or reported 
by any patient during the postoperative course.
The onset of action for articaine and bupivacaine 
as referred to lip and tongue numbness was similar 
(p=0.789), with a mean of 1.9 minutes (SD 1.2 minutes) 
and 1.8 minutes (SD 1.2 minutes) respectively. 
Similarly, no significant differences were observed 
between both groups regarding number or volume of 
reanesthesia (Table 1). Intraoperative reanesthesias were 
administered by means of intraligamentous infiltration, 
injecting 0.2 cc per infiltration. When a troncal reanesthesia 
was needed, 1.8 cc of anesthetic solution was injected. 
In six patients no additional anesthetic infiltrations were 
needed during any of the two surgical appointments. 
Bupivacaine Articaine 
Troncal reanesthesia 2 4 
Incision 1 1 
Flap elevation 0 0 
Luxation 0 1 
Tooth sectioning 0 0 
Tooth removal 11 9 
Suture 1 0 
Table 1. Number of additional anesthetic administrations. There 
were no significant differences between solutions (p>0.05).
Eight patients needed supplementary infiltrations in both 
surgeries, while four patients needed reanesthesia only 
with one of the two solutions (3 with bupivacaine and 
1 with articaine). No statistically significant differences 
were observed among solutions in this group of patients 
(McNemar test p=0.625).
Duration of surgery was also similar (p=0.185) with a 
mean of 23.7 minutes (SD 8.1 minutes) for bupivacaine 
vs. mean of 20.9 minutes (SD 4.5 minutes) for articaine. 
There were no statistically significant differences 
between solutions in pain perception, both interpreted 
by the surgeon or expressed by the patient (Table 2). 
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Pain rated by patient 
Bupivacaine
None Slight Moderate 
Articaine 
None 3 3 1
Slight 1 4 5
Moderate 1 0 0 
Pain rated by surgeon 
Bupivacaine
None Slight Moderate 
Articaine 
None 8 1 1
Slight 3 1 1
Moderate 1 2 0 
Table 2. Intraoperative global pain judged by the patient and by 
the surgeon. Figures represent number of patients. Categories 
“strong” and “unbearable pain” were not marked by any patient 
or surgeon in any procedure. Nine patients rated pain higher 
with bupivacaine than with articaine (shadowed cells, upper 
table); only 2 patients rated pain higher with articaine (p=0.112). 
Conversely, the surgeon rated pain perception higher in 6 cases 
with articaine (shadowed cells, lower table) and in 3 cases higher 
with bupivacaine (p=0.721).
However, surgeons tended to underestimate patients’ 
pain sensation (in 9 tooth extractions using bupivacaine 
the patient rated greater pain scores than that rated by 
the surgeon, and in no case did the surgeon rate higher 
pain scores than the patient). This underestimation was 
significant with bupivacaine (McNemar test p=0.029), 
but not with articaine (McNemar test p=0.149). 
When considering hemodynamic changes through 
surgery between groups, statistically significant higher 
levels of systolic blood pressure were observed in the 
articaine group (F=7.658; df=1; p=0.013). Systolic 
pressure varied significantly across time (F=3.0; df=4, 
p=0.024), gradually increasing form the baseline until 
the bone removal measurement and descending again 
at suture placement (Fig. 1). However, this variation 
across time was similar for both anesthetic solutions 
(F=0.377; df=2.366; p=0.723). Diastolic blood pressure 
was similar between groups (F=1.051; df=1; p=0.320), 
with no significant changes across time (F=2.482; 
df=2.268; p=0.090). Similar results were recorded 
considering oxygen saturation, where values did not 
differ between groups (F=1.831; df=1; p=0.194) and no 
significant changes occurred through time (F=1.666; 
df=2.288; p=0.199). Conversely, heart rate values varied 
significantly between groups across time (F=2.733; 
df=4; p=0.036). Higher heart rate levels were observed 
in the articaine group at tissue incision and bone removal 
(Fig. 2). 
Bupivacaine provided significantly longer lasting soft 
tissue anesthesia than articaine (Table 3).
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Fig. 1. Systolic arterial pressure changes over surgery. (Artic-
aine: blue line, Bupivacaine: green line).
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Fig. 2. Heart rate changes over surgery. (Articaine: blue line, Bupi-
vacaine: green line).
  Articaine Bupivacaine p 
Initial lip recovery 182.9 (78.5) 472.5 (186.5) 5.08·10-6
Final lip recovery 289.6 (82.0) 621.2 (148.4) 1.58·10-7
Initial tongue recovery 136.5 (59.7) 305.9 (153.6) 3.49·10-5
Final tongue recovery 238.1 (67.9) 512.1 (127.3) 3.08·10-7
Table 3. Mean duration (min) of soft tissue anesthesia (SD between 
parentheses). Articaine and bupivacaine were compared with a 
paired t-test.
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The postoperative VAS of pain varied significantly 
across time (F=2.114; df=12, p=0.017). Interestingly, the 
bupivacaine group had lower pain scores during day 1, 
being statistically significant at 2:00 PM (p=0.011) and 
4:00 PM (p=0.007) (Fig. 3). No statistically significant 
differences were found concerning the total intake of 
rescue analgesics during the first four postoperative 
days (Table 4).
result of his awareness of the differences in anesthetic 
duration between local anesthetics. Nevertheless, 
the analyzer had no commercial compromise and the 
strategy for data analysis had been defined before the 
results were available. 
In this study, no statistically significant differences on 
time to onset of action were observed between both 
solutions. Other studies have reported faster onsets 
p
Day 1 – 10 am .595 
Day 1 – 12 am .076 
Day 1 – 2 pm .011 
Day 1 – 4 pm .007 
Day 1 –  6 pm .127 
Day1 – 8 pm .322 
Day 1 – 10 pm .156 
Day 2 – 10 am .345 
Day 2 – 10 pm .334 
Day 3 – 10 am .861 
Day 3 – 10 pm .673 
Day 4 – 10 am .391 
Day 4 – 10 pm .188 
Fig. 3. P values corresponding to differences between visual analogue scale scores with both anesthetic solutions at 
different times. The blue line corresponds to articaine and the green line to bupivacaine. Differences were statisti-
cally significant on day 1 at 2:00 pm and 4:00 pm (shadowed cells). 
Articaine Bupivacaine 
Day 1 0.17 0.55 
Day 2 0.24 0 
Day 3 0 0 
Day 4 0.32 0 
Table 4. Mean number of  magnetic metami-
zol tablets per day. There were no significant 
differences between solutions (p>0.05).
Discussion
Our results suggest that 4% articaine and 0.5% 
bupivacaine, both with 1:200,000 epinephrine, have 
similar clinical efficacy in third molar surgery. Time 
to onset, need of additional anesthetic administration, 
intraoperative pain and hemodynamic effects were 
similar for both anesthetic solutions. The main 
difference between both solutions was the anesthetic 
effect duration; granting bupivacaine longer anesthetic 
periods, thus reducing early postoperative pain. 
Even though a triple blind scheme was intended, the 
statistical analyzer’s blinding was jeopardized as a 
with articaine, claiming lower pKa values (7.8) than 
bupivacaine (8.1) (15,24). Our results suggest that latency 
time is influenced by other factors besides pKa values. 
The anesthetic technique is probably an important factor, 
especially in the inferior alveolar nerve block, were the 
anesthetic solution is placed as close as possible to the 
inferior alveolar nerve, thus minimizing the need of 
dissemination of the anesthetic solution. Standardization 
of this troncal block is difficult as a result of anatomical 
variations among patients, differences between surgeons 
(right or left-handed, experience, etc.) and intraoperative 
circumstances (patient cooperation, operated side, 
etc.). Thus, we believe pKa values influence, but do not 
determine, onset of action, allowing similar and even 
shorter latency times for bupivacaine when compared 
to articaine solutions. 
Need of additional anesthetic administration was similar 
for both solutions, however unexpectedly frequent. In 
the study by Gregorio et al. (15), with a similar design 
to ours, 14% of the patients required complementary 
anesthetic infiltration during the surgeries in which 
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bupivacaine solution was used, while only 2% did so 
when articaine was administered. Conversely, a recent 
clinical trial with identical design demonstrated that 
the percentage of additional anesthesias was higher for 
articaine (47.4%) compared to bupivacaine (31.6%). In our 
study, 61% of the patients receiving bupivacaine and 50% 
receiving articaine requested for additional infiltration, 
especially with tooth avulsion maneuvers. The fact that 
patients did not perceive pain during tooth sectioning 
or luxation but did so during tooth avulsion maneuvers 
probably implies that patients could have misinterpreted 
traction forces as pain, making the blinded clinician 
administer more anesthesia. Supporting this idea, most 
of the patients who needed to be reanesthetized (8 out 
of 12 patients) required it during both surgeries, in other 
words, for both anesthetic solutions. This could suggest 
that the need for reanesthesia is more related to the 
patient than to the anesthetic solution itself. 
When surveying the patients on intraoperative anesthetic 
efficacy no statistically significant differences were 
found between solutions. Nonetheless, 9 patients 
rated their intraoperative pain awareness higher with 
bupivacaine, were as only 2 did so with articaine. These 
results could imply that bupivacaine performs slightly 
worse in controlling intraoperative pain, although 
these differences did not reach statistical significance. 
Intraoperative pain awareness has not been addressed 
directly in other studies, however indirect signs of 
incomplete anesthetic depth, such as need to administer 
additional anesthesia, could prove to some extent an 
inferior performance of bupivacaine as compared to 
articaine (15).
Interestingly, the results suggest that surgeons are 
unable to interpret precisely painful situations. 
Surgeon’s ratings on the patients’ pain experience 
underestimated those expressed by patients in 25% of 
the surgeries performed. This should make surgeons 
consider improving patient-operator communication, in 
order to increase patient satisfaction and provide better 
care. 
An important issue when studying the application 
of long lasting anesthetics in surgery is their ability 
to reduce or delay postoperative pain. In our study 
statistical significant lower pain levels were observed 
with bupivacaine between the fifth and the ninth 
postoperative hours with respect to articaine. This 
time period extends from the point where the articaine 
solution starts to wear off and the bupivacaine is 
still acting, until the moment where the anesthetic 
action of the bupivacaine solution disappears. Several 
studies confirm the ability of bupivacaine to prolong 
the analgesic period for inferior alveolar nerve block 
anesthesia, providing analgesia during the first 8 to 
12 hours, which is the period of maximum pain after 
third molar surgery (9,10,14,26). Nevertheless, other 
studies fail to prove this residual analgesic effect (15) 
and even have shown lower early postoperative pain 
values with articaine when compared to bupivacaine 
(24). Differences between studies most likely respond 
to methodological design dissimilarities. It is therefore 
necessary to perform further research using greater 
sample sizes and strict parameter recordings to try to 
answer this critical uncertainty.  
Even if bupivacaine could grant milder early 
postoperative periods, its extended anesthetic effect may 
be a drawback for some patients since prolonged periods 
of soft tissue anesthesia can cause soft tissue trauma as 
well as eating or speaking disability. Rosenquist and 
Nystrom (27) reported that 34% of patients described 
prolonged soft tissue numbness caused by bupivacaine 
anesthesia as unpleasant. In a further study conducted 
by Rosenquist et al. (18) some patients preferred having 
some postoperative pain if lip sensibility was recovered 
earlier. Mean lip anesthesia duration for bupivacaine in 
our study was 621 minutes. Significant differences in 
duration of lip anesthesia have been reported in other 
studies using similar volumes of the same anesthetic 
solution (306 minutes (24), 315 minutes (15), 411 minutes 
(14), 586 minutes (28), 643 minutes (11)). Information 
about this issue should be given to the patient, evaluating 
his preferences with regard to extended lip anesthesia. 
Advice should be given to avoid soft tissue trauma. In 
our study no patient reported any traumatism on cheeks 
or lips. A suggestion to minimize this nuisance could be 
using long lasting anesthetic solutions when surgeries 
are performed in the afternoons. This would permit 
the patient going to sleep with no pain, reducing the 
potential hours of discomfort.
Oxygen saturation, heart rate and blood pressure 
suffered variations during stressful steps of surgery, 
as reported by Alemany-Martinez et al. (29). No 
significant changes were observed between anesthetic 
solutions with respect to oxygen saturation or diastolic 
blood pressure. However, higher systolic blood pressure 
levels and higher heart rate values reported in the 
articaine group at soft tissue incision and bone removal 
could be interpreted as a body reactions to a hectic 
or painful situation attributable to a lower anesthetic 
depth level compared to that obtained with bupivacaine. 
Nevertheless, results should be interpreted with caution 
since this reading contradicts the fact that patient’s 
reported similar or even worse intraoperative pain 
when receiving bupivacaine.  
Even though bupivacaine has an overall good safety 
profile, it could have severe adverse effects on the central 
nervous system and cardiovascular system (19,30). For 
this reason, routine aspiration before injection is more 
than mandatory. Blood concentrations of bupivacaine 
studied by Bouloux et al. (10) after an inferior alveolar 
nerve block suggest that oral tissues modify the 
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pharmacokinetics of the drug, slowing its vascular 
absorption, therefore decreasing its the potential 
toxicity. The present study failed to detect any signs or 
symptoms of central nervous system or cardiovascular 
toxicity in any subject with either local anesthetic.
Within the limitations of this study, it can be concluded 
that anesthetic success in third molar surgery is similar 
with 4% articaine and 0.5% bupivacaine, both with 
1:200,000 epinephrine. Both solutions exhibit similar 
latency times and intraoperative efficacy. Bupivacaine 
intraoperative pain control seemed slightly worse. 
However, bupivacaine reduced pain scores during the 
early postoperative period, when the maximum intensity 
of pain occurs. This extended anesthetic effect entailed, 
nevertheless, prolonged periods of soft tissue numbness, 
which may be a nuisance. No significant changes were 
observed between anesthetic solutions with respect to 
diastolic blood pressure or oxygen saturation, although 
systolic blood pressure and heart rate were higher with 
articaine during incision and bone removal. Therefore, 
bupivacaine seems a valid alternative to articaine, 
particularly in the prevention of early postoperative 
pain.
References
1. Marciani RD. Third molar removal: an overview of indications, 
imaging, evaluation, and assessment of risk. Oral Maxillofac Surg 
Clin North Am. 2007;19:1-13.
2. Bagheri SC, Khan HA. Extraction versus nonextraction man-
agement of third molars. Oral Maxillofac Surg Clin North Am. 
2007;19:15-21.
3. Esposito M, Coulthard P. Impacted wisdom teeth. Clin Evid (On-
line). 2008;2008:1302. 
4. Bouloux GF, Steed MB, Perciaccante VJ. Complications of third 
molar surgery. Oral Maxillofac Surg Clin North Am. 2007;19:117-
28.
5. Kim K, Brar P, Jakubowski J, Kaltman S, Lopez E. The use of cor-
ticosteroids and nonsteroidal antiinflammatory medication for the 
management of pain and inflammation after third molar surgery: a 
review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod. 2009;107:630-40.
6. Markiewicz MR, Brady MF, Ding EL, Dodson TB. Corticos-
teroids reduce postoperative morbidity after third molar surgery: 
a systematic review and meta-analysis. J Oral Maxillofac Surg. 
2008;66:1881-94.
7. Meechan JG, Seymour RA. The use of third molar surgery in clini-
cal pharmacology. Br J Oral Maxillofac Surg. 1993;31:360-5.
8. Romano JA, Jr. Psychological and physiological factors in pain 
perception. Bull Monmouth Ocean Cty Dent Soc. 1975;34:14-6.
9. Neal JA, Welch TB, Halliday RW. Analysis of the analgesic ef-
ficacy and cost-effective use of long-acting local anesthetics in 
outpatient third molar surgery. Oral Surg Oral Med Oral Pathol. 
1993;75:283-5.
10. Bouloux GF, Punnia-Moorthy A. Bupivacaine versus lidocaine 
for third molar surgery: a double-blind, randomized, crossover study. 
J Oral Maxillofac Surg. 1999;57:510-4.
11. Branco FP, Ranali J, Ambrosano GM, Volpato MC. A double-
blind comparison of 0.5% bupivacaine with 1:200,000 epinephrine 
and 0.5% levobupivacaine with 1:200,000 epinephrine for the inferi-
or alveolar nerve block. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod. 2006;101:442-7.
12. Colombini BL, Modena KC, Calvo AM, Sakai VT, Giglio FP, 
Dionisio TJ, et al. Articaine and mepivacaine efficacy in postopera-
tive analgesia for lower third molar removal: a double-blind, random-
ized, crossover study. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod. 2006;102:169-74.
13. Danielsson K, Evers H, Holmlund A, Kjellman O, Nordenram A, 
Persson NE. Long-acting local anaesthetics in oral surgery. Clini-
cal evaluation of bupivacaine and etidocaine for mandibular nerve 
block. Int J Oral Maxillofac Surg. 1986;15:119-26.
14. Fernandez C, Reader A, Beck M, Nusstein J. A prospective, ran-
domized, double-blind comparison of bupivacaine and lidocaine for 
inferior alveolar nerve blocks. J Endod. 2005;31:499-503.
15. Gregorio LV, Giglio FP, Sakai VT, Modena KC, Colombini BL, 
Calvo AM, et al. A comparison of the clinical anesthetic efficacy of 
4% articaine and 0.5% bupivacaine (both with 1:200,000 epineph-
rine) for lower third molar removal. Oral Surg Oral Med Oral Pathol 
Oral Radiol Endod. 2008;106:19-28.
16. Laskin JL, Wallace WR, DeLeo B. Use of bupivacaine hydro-
chloride in oral surgery-a clinical study. J Oral Surg. 1977;35:25-9.
17. Rood JP, Coulthard P, Snowdon AT, Gennery BA. Safety and ef-
ficacy of levobupivacaine for postoperative pain relief after the surgi-
cal removal of impacted third molars: a comparison with lignocaine 
and adrenaline. Br J Oral Maxillofac Surg. 2002;40:491-6.
18. Rosenquist JB, Rosenquist KI, Lee PK. Comparison between li-
docaine and bupivacaine as local anesthetics with diflunisal for post-
operative pain control after lower third molar surgery. Anesth Prog. 
1988;35:1-4.
19. Sisk AL. Long-acting local anesthetics in dentistry. Anesth Prog. 
1992;39:53-60.
20. Malamed SF, Gagnon S, Leblanc D. Efficacy of articaine: a new 
amide local anesthetic. J Am Dent Assoc. 2000;131:635-42.
21. Seymour RA, Walton JG. Pain control after third molar surgery. 
Int J Oral Surg. 1984;13:457-85.
22. Koerner KR, Taylor SE. Pharmacologic considerations in the 
management of oral surgery patients in general dental practice. Dent 
Clin North Am. 1994;38:237-54.
23. Chapman PJ. Postoperative pain control for outpatient oral sur-
gery. Int J Oral Maxillofac Surg. 1987;16:319-24.
24. Trullenque-Eriksson A, Guisado-Moya B. Comparative study of 
two local anesthetics in the surgical extraction of mandibular third 
molars: bupivacaine and articaine. Med Oral Patol Oral Cir Bucal. 
2011;16:e390-6.
25. Leonard MS. Removing third molars: a review for the general 
practitioner. J Am Dent Assoc. 1992;123:77-8, 81-2, 85-6. 
26. Nayyar MS, Yates C. Bupivacaine as pre-emptive analgesia in 
third molar surgery: Randomised controlled trial. Br J Oral Maxil-
lofac Surg. 2006;44:501-3.
27. Rosenquist JB, Nystrom E. Long-acting analgesic or long-acting 
local anesthetic in controlling immediate postoperative pain after 
lower third molar surgery. Anesth Prog. 1987;34:6-9.
28. Volpato MC, Ranali J, Ramacciato JC, de Oliveira PC, Ambro-
sano GM, Groppo FC. Anesthetic efficacy of bupivacaine solutions 
in inferior alveolar nerve block.Anesth Prog. 2005;52:132-5. 
29. Alemany-Martinez A, Valmaseda-Castellon E, Berini-Aytes L, 
Gay-Escoda C. Hemodynamic changes during the surgical removal 
of lower third molars. J Oral Maxillofac Surg. 2008;66:453-61.
30. Bacsik CJ, Swift JQ, Hargreaves KM. Toxic systemic reactions 
of bupivacaine and etidocaine. Oral Surg Oral Med Oral Pathol Oral 
Radiol Endod. 1995;79:18-23.
